CASI Pharmaceuticals Announces Second Quarter 2021 Financial Results
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/18/2026
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Oil slides after China asks Iran to limit Houthi attacks on Saudi oil facilities
- Warren Buffett transitions to Berkshire’s chairman emeritus
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
CASI Pharmaceuticals (CASI) PT Raised to $6 at Oppenheimer
August 13, 2021 9:21 AM EDTOppenheimer analyst Leland Gershell raised the price target on CASI Pharmaceuticals (NASDAQ: CASI) to $6.00 (from $5.00) while maintaining an Outperform rating.
The analyst commented, "CASI reported another quarter of solid Evomela growth, posting 2Q21 revenue of $7.1M (+25% Q/Q, +173% Y/Y) vs. our $6.2M... More
CASI Pharma (CASI) Tops Q2 EPS by 2c
August 12, 2021 7:18 AM EDTCASI Pharma (NASDAQ: CASI) reported Q2 EPS of ($0.05), $0.02 better than the analyst estimate of ($0.07). Revenue for the quarter came in at $7.16 million versus the consensus estimate of $6.02 million.
Revenue Growth Guidance in 2021 Revised to Exceed 80% Over 2020For earnings history and earnings-related data on CASI Pharma (CASI) click here.
... More